의료 육안 검사 서비스 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 기술별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Healthcare Visual Inspection Services Market Growth & Trends:

The global healthcare visual inspection services market size is expected to reach USD 7.08 billion by 2030, registering a CAGR of 9.97% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growth in the market can be attributed to benefits offered by healthcare visual inspection, such as cost savings, increased quality assurance, revolutionizing quality control processes, and enhanced operational efficiency. Besides, in pharmaceutical and medical devices, the inspection process improves the quality, further saving costs for manufacturers.

In addition, visual inspection systems support healthcare companies in harnessing their capabilities, further elevating their quality control standards, driving cost efficiencies, and optimizing production processes to stay competitive in the dynamic industrial landscape. It further supports delivering superior products consistently, reducing waste, and efficiently operating, ultimately fueling growth and success.

Moreover, automation, artificial intelligence (AI), and machine learning are some of the key factors fueling the market. Manufacturers are increasingly opting for healthcare visual inspection to enhance efficiency, reduce human error, and improve defect detection. Besides, rising investments in biopharmaceutical research and development (R&D) and growing presence of established contract development and manufacturing organizations (CDMOs), contract manufacturing organizations (CMOs), and contract research organizations (CROs) contribute to market growth.

Moreover, stringent regulatory requirements from the FDA, EMA, and MHRA have made healthcare visual inspection services essential for ensuring the safety, efficacy, and compliance of pharmaceutical and medical device products. Besides, standards like USP <790>, USP <1790>, and EU GMP Annex 1 are necessary for particulate matter detection and improved inspection systems. Hence, to comply, most manufacturers are integrating real-time data analytics, predictive maintenance, and AI-driven defect classification to ensure regulatory adherence and minimize recalls.

Hence, healthcare companies are shifting towards visual inspection services for automation, real-time compliance monitoring, and AI-assisted decision-making. These advancements enhance precision, efficiency, and product safety, reinforcing the importance of innovation in ensuring high-quality healthcare manufacturing. Therefore, this has led to an increasing need for these services, leading to increasing outsourcing of visual inspections and seeking cost-effective and specialized expertise with their emerging pipelines. Such factors are expected to drive the market over the estimated period.

Healthcare Visual Inspection Services Market Report Highlights:

• The pharmaceutical segment dominated the market, with a share of 65.15% in 2024. Growth in the segment can be attributed to the increasing focus on quality assurance of pharmaceutical products & medical devices. In addition, cost efficiency, product compliance, and a growing focus on product safety are expected to drive the segment growth.
• Based on technology, the semi-automated visual inspection (SAVI) segment held the largest market share in 2024, attributed to the stringent regulatory requirements, growing demand for medical devices & pharmaceutical drugs, and rapid adoption of automation. Besides, semi-automation offers an easy and practical examination of ampoules, vials, cartridges, and syringes carrying injectable liquids, powders, or freeze-dried products.
• Based on the end use, the pharmaceutical and biopharmaceutical companies segment dominated the market, accounting for 49.82% in 2024. This is attributable to increasing pharmaceutical drug demand, the growing burden of diseases, rising cost-efficiency service, growing R&D investment, and a growing focus on product safety.
• North America market held the largest market share of 40.68% in 2024. The growing demand for outsourcing and the presence of established market players in countries like the U.S., Canada, and North America is expected to drive the market. Furthermore, established market players within the region offering efficient healthcare visual inspection services in the U.S. is one of the key factors propelling the market growth.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Technology
  • 1.2.3. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Healthcare Visual Inspection Services Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technological Advancements
• 3.4. Clinical trials volume analysis (2024)
• 3.5. Healthcare Visual Inspection Services Market Analysis Tools
  • 3.5.1. Industry Analysis - Porter's Five Analysis
  • 3.5.2. PESTEL Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Healthcare Visual Inspection Services Market: Product Estimates & Trend Analysis

• 4.1. Healthcare Visual Inspection Services Market, By Product: Segment Dashboard
• 4.2. Healthcare Visual Inspection Services Market, By Product: Movement Analysis
• 4.3. Healthcare Visual Inspection Services Market Estimates & Forecasts, By Product, 2018 - 2030
• 4.4. Pharmaceutical
  • 4.4.1. Pharmaceutical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Medical Device
  • 4.5.1. Medical Device Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Healthcare Visual Inspection Services Market: Technology Estimates & Trend Analysis

• 5.1. Healthcare Visual Inspection Services Market, By Technology: Segment Dashboard
• 5.2. Healthcare Visual Inspection Services Market, By Technology: Movement Analysis
• 5.3. Healthcare Visual Inspection Services Market Estimates & Forecasts, By Technology, 2018 - 2030
• 5.4. Manual Visual Inspection (MVI)
  • 5.4.1. Manual Visual Inspection (MVI) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Semi-Automated Visual Inspection (SAVI)
  • 5.5.1. Semi-Automated Visual Inspection (SAVI) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Automated Visual Inspection (AVI)
  • 5.6.1. Automated Visual Inspection (AVI) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Healthcare Visual Inspection Services Market: End Use Estimates & Trend Analysis

• 6.1. Healthcare Visual Inspection Services Market, By End Use: Segment Dashboard
• 6.2. Healthcare Visual Inspection Services Market, By End Use: Movement Analysis
• 6.3. Healthcare Visual Inspection Services Market Estimates & Forecasts, By Drug Type, 2018 - 2030
• 6.4. Pharmaceutical & Biopharmaceutical Companies
  • 6.4.1. Pharmaceutical & Biopharmaceutical Companies Market, 2018 to 2030, (USD Million)
• 6.5. Medical Device Companies
  • 6.5.1. Medical Device Companies Market, 2018 to 2030, (USD Million)
• 6.6. Others
  • 6.6.1. Others Market, 2018 to 2030, (USD Million)

Chapter 7. Healthcare Visual Inspection Services Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. North America
  • 7.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. U.S
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Thailand
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Australia
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Company Market Share Analysis, 2023/24
• 8.3. Company Profiles
  • 8.3.1. Catalent, Inc.
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Charles River Laboratories
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Jabil Inc.
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Lonza Group
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Grand River Aseptic Manufacturing.
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Vetter Pharma
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. NIVAGEN
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Recipharm AB
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Samsung Biologics
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. SGS SA
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. West Pharmaceutical Services, Inc.
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Service Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. Adragos Pharma.
    • 8.3.12.1. Company Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Service Benchmarking
    • 8.3.12.4. Strategic Initiatives

Chapter 9 Key Recommendations